Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer

IMPORTANCE: Trastuzumab improves outcomes in patients with ERBB2-positive (formerly HER2) breast cancer but is associated with treatment-induced cardiotoxicity, most commonly manifest by an asymptomatic decline in left ventricular ejection fraction (LVEF). Little is known to date regarding the long-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Cardiol
Autors principals: Yu, Anthony F., Flynn, Jessica R., Moskowitz, Chaya S., Scott, Jessica M., Oeffinger, Kevin C., Dang, Chau T., Liu, Jennifer E., Jones, Lee W., Steingart, Richard M.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990842/
https://ncbi.nlm.nih.gov/pubmed/31939997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.5586
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars